{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 10,
        "end": 19
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 24,
        "end": 28
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 97,
        "end": 113
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 131,
        "end": 135
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 131,
        "end": 156
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 24,
        "end": 38
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "25589624_2",
  "text": "PURPOSE : Veliparib , a PARP inhibitor , demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA -mutant solid tumors in a phase I trial ."
}
